Clinical Trial Update: Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study of rilzabrutinib in adults with moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED